Compare FTCI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | TLSA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 124.0M |
| IPO Year | 2021 | 2017 |
| Metric | FTCI | TLSA |
|---|---|---|
| Price | $2.20 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.80 | N/A |
| AVG Volume (30 Days) | 230.3K | ★ 832.9K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $2.28 | $0.87 |
| 52 Week High | $12.75 | $2.35 |
| Indicator | FTCI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 58.03 |
| Support Level | N/A | $1.14 |
| Resistance Level | $5.40 | $1.15 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 0.00 | 81.98 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.